.png)
.png)
Professor of Medicine
Duke University Medical Center
Disclosure(s): Affinergy: Grant/Research Support, Honoraria; Affinium: Honoraria; Amphliphi Biosciences: Honoraria; ArcBio: Stocks/Bonds; Basilea: Grant/Research Support, Honoraria; Bayer: Honoraria; C3J: Honoraria; Cerexa/Forest/Actavis/Allergan: Grant/Research Support; Contrafect: Grant/Research Support, Honoraria; Cubist/Merck: Grant/Research Support; Debiopharm: Grant/Research Support; Deep Blue: Grant/Research Support; Destiny: Honoraria; Genentech: Grant/Research Support, Honoraria; Integrated Biotherapeutics: Honoraria; Janssen: Grant/Research Support, Honoraria; Karius: Grant/Research Support; Medicines Co.: Honoraria; MedImmune: Grant/Research Support, Honoraria; NIH: Grant/Research Support; Novartis: Grant/Research Support, Honoraria; Pfizer: Grant/Research Support; Regeneron: Grant/Research Support, Honoraria; Sepsis diagnostics: Sepsis diagnostics patent pending; UpToDate: Royalties; Valanbio: Stocks/Bonds
Vance Fowler, MD, MHS is Florence McAlister Distinguished Professor in the Departments of Medicine and Molecular Genetics & Microbiology, Duke University Medical Center. Dr. Fowler has over 2 decades of continuous support as PI from the NIH for clinical and translational research in Staphylococcus aureus and other drug-resistant bacterial infections. Dr. Fowler created the S. aureus Bacteremia Group, co-founded the International Collaboration on Endocarditis, and is Communicating PI of the Antibacterial Resistance Leadership Group.